Macrocure logo
Source: Macrocure

Macrocure Ltd. Prices Initial Public Offering

PETACH TIKVA, Israel, July 30, 2014 (GLOBE NEWSWIRE) -- Macrocure Ltd. ("Macrocure") announced today the pricing of its initial public offering of 5,350,000 ordinary shares at a price to the public of $10.00 per share. The shares are expected to begin trading on The NASDAQ Global Market on July 31, 2014 under the symbol "MCUR." Macrocure has granted the underwriters a 30-day option to purchase up to 802,500 additional shares. The offering is expected to close on or about August 5, 2014 subject to the satisfaction of customary closing conditions.

Credit Suisse Securities (USA) LLC and Jefferies LLC are acting as joint book-running managers for the offering. Nomura Securities International, Inc. and Oppenheimer & Co. Inc. are acting as co-managers.

The offering of these securities will be made only by means of a written prospectus. A copy of the prospectus related to the offering may be obtained from Credit Suisse Securities (USA) LLC, Attention: Prospectus Department, One Madison Avenue, New York, New York 10010, or by phone (800) 221-1037 or Jefferies LLC, Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY, 10022 or by telephone at 877-547-6340.

A registration statement relating to the initial public offering has been filed with and declared effective by the Securities and Exchange Commission. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Macrocure Ltd.

Macrocure Ltd. is a regenerative medicine company focused on developing, manufacturing and commercializing novel cell therapy products to address unmet needs in the treatment of chronic and other hard-to-heal wounds, such as diabetic foot ulcers (DFUs) and venous leg ulcers (VLUs). The Company's novel approach is to treat and close chronic and other hard-to-heal wounds by injecting the human body's own wound healing and regenerative components directly into the wound itself.

Cautionary Note Regarding Forward-Looking Statements

This press release contains "forward-looking statements" relating to future events, such as statements regarding the closing of the offering. Forward-looking statements are based on Macrocure's current knowledge and its present beliefs and expectations regarding possible future events and are subject to risks, uncertainties and assumptions. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of several factors. The forward-looking statements made herein speak only as of the date of this release and Macrocure undertakes no obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as otherwise required by law.

Francesca DeMartino
Investor Relations & Corporate Communications
+1 (310) 739-6476